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Abstract  
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease. Half of patients 
experience debilitating fatigue which is currently untreatable. Previous studies have shown 
muscle bioenergetic abnormalities in PBC, including increased muscle acidosis with exercise 
linked to the anti-mitochondrial antibody (AMA) diagnostic of the disease, and reduced 
anaerobic threshold. In this study we addressed the hypothesis that fatigue in PBC is driven 
by muscle bioenergetic abnormality related to AMA, and that AMA reduction with B-cell 
depletion therapy will improve fatigue. In our single-centred Phase II randomised controlled 
trial (RCT)  57 participants aged ≥18 years with PBC and moderate or severe fatigue were 
randomized to receive 2 doses of either rituximab (1000mg) or saline (placebo). The primary 
outcome measure was fatigue severity assessed using the PBC-40 fatigue domain at 3 
months. Secondary outcomes measures included patient-reported outcomes, 
immunological and bioenergetics disease parameters. Experimental outcomes included 
biochemical markers of disease severity. Improvement in fatigue score at 3 months was 
seen in both arms, with no significant difference (adjusted mean difference -0.9 95%CI -4.6 
to 3.1). Little difference was observed in other patient reported outcomes or physical 
activity.  Significant anaerobic threshold improvement was seen in the Rituximab group only 
but this was not associated with fatigue improvement. No treatment-emergent SAEs were 
seen. 
Conclusions: Rituximab was safe over the 12 month study period but showed no evidence of 
effectiveness for the treatment of fatigue in PBC. Anaerobic threshold improvement was 
seen; potentially linking AMA with muscle bioenergetics dysfunction, however, this was not 
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related to improvement in fatigue. Rituximab had some evidence of a beneficial effect on 
alkaline phosphatase levels in this largely UDCA-responding, early disease stage cohort.  
 
Introduction 
PBC is a chronic liver disease characterized by loss of intra-hepatic bile ducts accompanied 
by progressive cholestasis (1). 50% of patients experience moderate or severe fatigue; a 
debilitating symptom affecting quality of life and contributing to social isolation and 
significant quality of life impairment (2-4). Fatigue, the symptom most frequently reported 
by PBC patients [2-4],  can occur at any point in the disease course, and its severity is 
unrelated to liver disease activity or degree of liver damage and is not improved by current 
first or second line therapy (5, 6),(7) . Given its impact, and lack of response to therapy, 
increasing understanding of, and treatment for, fatigue has been highlighted by patients as 
a priority for research. There have, however, been only 2 placebo controlled trials with 
fatigue as the primary endpoint. Neither of these trials, exploring the use of Fluoxetine and 
Modafanil, showed evidence of benefit (8, 9). At the time of the design of this trial 
evidence was emerging to suggest that the anti-CD20 biological agent Rituximab was 
effective for the reduction of fatigue in a number of immune conditions, including Primary 
Sjogrens Syndrome, a condition which shows an association with PBC (10-13). This raised 
the question as to the possible value of Rituximab as a fatigue modifying treatment in PBC. 
The potential value was supported by a possible direct biological mechanism. PBC is 
characterized immunologically by the presence of AMA, a population of  high titer 
autoantibodies directed at Pyruvate Dehydrogenase Complex (PDC), an enzyme complex 
which play a critical role in cellular bioenergetic function linking glycolysis and the Krebs 
cycle (14). Anti-PDC antibodies from PBC patients are highly effective, in vitro at least, at 
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blocking PDC function (15). Clinically, PBC patients exhibit both central and peripheral 
elements to their fatigue. The peripheral component, likened by patients to feeling that 
their “batteries are running down”, is associated with inability to sustain repeat muscle 
contraction. Investigation of this phenomenon, using novel magnetic resonance 
spectroscopy approaches, revealed marked muscle acidosis with exercise, related to 
mitochondrial dysfunction, and a prolongation in the time taken for recovery of muscle 
acidosis following discontinuation of exercise which was related to fatigue severity (16). 
The degree of mitochondrial dysfunction was related to serum anti-PDC level (17). In 
separate approaches PBC patients have been shown to have lower anaerobic threshold 
levels than matched normal and cholestatic controls (18). Taken together, these 
observations point to the possibility of dysregulation of aerobic metabolism in muscle in 
PBC, with excessive or inappropriate utilization of the anaerobic lactate dehydrogenase 
pathway. The link between anti-PDC levels and mitochondrial dysfunction, and the capacity 
of anti-PDC to block PDC function led us to postulate that anti-PDC may be a driver for 
metabolic insult in PBC that this insult may contribute to fatigue and this effect may be 
reduced by Rituximab as a B-cell targeting drug.  A pilot study completed in Canada had 
provided some evidence to support this contention (19). 
The objectives of the current study were to assess whether Rituximab improved moderate 
or severe fatigue in patients with PBC, to assess the safety and tolerability of Rituximab in 
PBC and to assess the effect of Rituximab bioenergetics abnormality potentially linked to 
fatigue. 
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Methods 
The protocol for this study has been published and the study design, criteria and 
procedures outlined in detail (20).   
Subjects 
Seventy-one participants aged ≥18 years with PBC and clinically significant fatigue (as 
defined by a PBC-40 fatigue domain score of >33 (mean + 2SD for a normal control 
population (4)) were screened at a single clinical center at Newcastle, led and managed by 
the Newcastle upon Tyne Hospitals NHS Foundation Trust. Fifty-seven participants were 
randomized in a 1:1 ratio to receive either Rituximab (1000mg) (n=28) or saline 
intravenous infusion on days 1 and 15 (placebo, n=29). The infusions were delivered in a 
double-blind manner using the same protocol. All participants had a clinical diagnosis of 
definite (meeting all 3 criteria) or probable (meeting 2 of 3 criteria) primary biliary 
cholangitis (cirrhosis) established using recognized epidemiological criteria: 
a) Cholestatic liver biochemistry at disease outset (defined as elevation in the serum 
Alkaline phosphatase (ALP) level or gamma-glutamyl-transferase (GGT)) 
b) Associated autoantibody (anti-mitochondrial antibody or PBC-associated 
antinuclear antibody by immunofluorescence or anti-PDC, anti-Gp210 or anti-
Sp100) at a titer of ≥1:40 
c) Diagnostic or compatible liver biopsy 
 
Patients in whom ALP and GGT return to normal with therapy retained their diagnostic 
status. 
Inclusion & Exclusion Criteria 
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The study criteria are published in detail elsewhere. The key study characteristics were 
Inclusion  
• Clinically significant fatigue (PBC-40 fatigue domain score >33 (4)) 
• Presence of AMA at a titer of >1:40 
• Hb  >9g/L,  absolute  neutrophil  count  >1.5x109/L, platelet count > 50x109/L 
• Bilirubin ≤ 50 μmol 
• INR ≤ 1.5 
• Child Pugh score < 7 
• Adequate renal function; Cockcroft and Gault estimation > 40ml/min 
• age ≥ 18 years 
• Patient had capacity and provided written informed consent. 
 
Exclusion  
• Advanced or decompensated liver disease 
•  Aspartate transaminase (AST) / Alanine transaminase (ALT) 4 x upper limit of Normal 
(ULN) 
• History or presence of other concomitant liver diseases  
• Previous treatment with B-cell depleting therapy 
• Previous history of aberrant response or intolerance to immunological agents or to 
other study agents 
• Presence  of  clinically significant  untreated  intercurrent  medical  condition  itself  
associated  with fatigue including depressive illness 
• Statin use (current or  use within 3 months of enrolment) 
• Ongoing participation in other clinical trials or exposure to any investigational agent 4 
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weeks prior to baseline or within < 5 half-lives of the investigational drug 
• Intercurrent active or latent infection  
• Intercurrent immuno-compromised state 
• Malignancy (other than basal cell carcinoma) within the last 10 years 
 
Study Design 
This was a single centered phase II, double-blind, randomized controlled trial. Participants 
received two infusions on days 1 and 15 and were then followed-up at 3, 6, 9 and 12 
months. The primary endpoint was improvement in fatigue severity at 3 months with 
extended follow-up (up to 12 months) to explore the stability over time of clinical or 
phenotypic change.  
 
Randomization 
Randomization was conducted by the Newcastle Clinical Trials Unit (NCTU) web-based 
system on a 1:1 ratio using random-permuted blocks with random block length. The 
randomization system generated a treatment number for each participant that linked to 
the corresponding allocated study drug. Patients could only be randomized into the study 
by an authorized member of research team, as detailed on the Study Delegation Log.  
 
Experimental Intervention 
The investigational medicinal product used in the clinical trial was Rituximab, 1000 mg IV 
(MabThera®). This product was approved by the European Agency for the Evaluation of 
Medicinal Products (MA number: EU/1/98/067/002) and license held by Roche Products 
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Ltd. The product was supplied as vials containing 500 mg of Rituximab at a concentration 
of 10mg/ml and stored between 2°C and 8 °C, in a secure location in their original 
packaging to avoid light damage. Supplies of Rituximab were labelled as investigational 
medicinal product (IMP). Patients randomized to receive Rituximab therapy were given 
treatment at the infusion rates recommended for rheumatoid arthritis (RA) patients (i.e. 
for the first infusion at an initial rate of 50 mg/hr.; after the first 30 minutes it could be 
escalated in 50 mg/hr. increments every 30 minutes, to a maximum of 400 mg/hr.). Second 
doses were infused at an initial rate of 100 mg/hr., and increased by 100 mg/hr. at 30 min 
intervals to a max of 400mg/hr (21). The control infusion was delivered in a double blind 
manner to participants under the supervision of a clinician (all clinical staff were blinded as 
to the study arm with the infusions prepared in centralized pharmacy facility and provided 
to the clinical research facility in the anonymized form. In line with recommendations for 
the administration of Rituximab in other conditions, patients received a conditioning 
regimen prior to the infusions of study medication or placebo. This conditioning regimen 
was administered 30 minutes prior to infusion of study medication and comprised: 
paracetamol 1g PO; chlorpheniramine 10mg IV; and methyl prednisolone 100mg IV. 
Conditioning was given to all participants to maintain the blind.  
 
Outcomes 
The primary outcome measure was the fatigue domain score from the PBC-40 
questionnaire at 3 months. The PBC-40 is a fully validated patient-derived quality of life 
measure which includes a fatigue domain with a potential value range of 11 to 55 and 
higher values denoting worse fatigue)(22). The time course of the comparison between 
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intervention and control groups over the 12 month follow-up period was also assessed. 
Secondary outcome measures included the following: 
1) Other symptom severity assessed by the relevant domains of the PBC-40 (Itch, 
Cognition, Social, Emotional and Symptoms) (22). Anxiety and depression were 
assessed by Hospital Anxiety and Depression Scale (HADS) score (range 0-42) (23); 
daytime somnolence by Epworth Sleeping Scale (ESS) (range 0-24) (24); vasomotor 
autonomic symptoms using Orthostatic Grading Scale (OGS) (range 0-20)  (25); 
functional status by Patient-Reported Outcomes Measurement Information System- 
Health Assessment Questionnaire (PROMIS HAQ) (range 0-100) (26), and cognitive 
functionality by Cognitive failure questionnaire (COGFAIL) (range 0-100) (27), where 
higher scores indicate worse outcome. 
2) Fatigue diaries using both structured (quantitative) and unstructured (qualitative) 
methods of data collection undertaken 6 times during the study (for a week at baseline 
and during the first weeks of months 1, 3, 6, 9 and 12.  
3) Physical activity monitoring using wrist worn tri-axial GENEActiv accelerometers 
(Activinsights Ltd., Cambridgeshire, UK). The accelerometer was worn continuously on 
the right wrist for a period of 7 days in free-living conditions. Patients were included in 
the analysis if they had worn the monitor for a minimum time period of 5 days (at least 
one days on the weekend). Only days with at least 22 hours of valid data were retained 
for analysis. Activity data are presented as Euclidian Norm minus One (ENMO) values for 
the per hour average of the whole assessment period, and for the highest activity 5 
hours of the period. Higher values indicate greater activity levels. 
4) Anaerobic threshold (AT) assessed using conventional Cardiopulmonary Exercising (CPX). 
Participants cycled on a stationary ergometer (Corival, Lode, and Nederland) at between 
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60-70rpm. Anaerobic threshold was determined using the computerized v-slope method 
at baseline and 12 week follow up. 
5) Muscle bioenergetic function was assessed using Magnetic Resonance Spectroscopy at 
baseline and at 12 weeks using a 3T Intera Achieva scanner (Philips, Best, and NL). The 
protocol used for acquisition and analysis has been described in detail in published 
protocols(17). 
6) Quantification and phenotyping of total B-cell populations and B-cell subsets was 
undertaken using a standard Fluorescence-activated cell sorting (FACS) based approach. 
Total B-cells levels in peripheral blood were evaluated using a direct immune-
fluorescence reagent (Fast Immune CD19/CD69/CD45, BD Biosciences). Anti-PDC 
antibody total and individual isotype levels were studied on day 0 and at 12 weeks using 
a well-established Enzyme Linked Immunosorbent Assay (ELISA) developed within our 
research group. 
Change in liver serum biochemistry was an exploratory outcome measure.  
 
Statistical Analysis 
The study was planned to detect a mean change in PBC-40 fatigue domain score of 5 units at 
3 months follow-up (a difference demonstrated in our population-based studies to be 
associated with significantly higher levels of social function) (5). Previous studies had shown 
a standard deviation of 8 units and a correlation of 0.6 between baseline and follow-up, so 
using a power of 90% and a 5% significance level, this required outcome data from 35 
participants per arm. A total of 78 participants (39 per arm) was planned to be recruited and 
randomized; assuming 10% attrition at 3-month follow-up. However, since recruitment was 
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slower than expected, trial recruitment was extended by 6-months and the power of the 
trial was reduced to 80% with a revised target sample size of 58 participants (29 per arm). 
All analyses were performed on the intention-to-treat (ITT) population. If at least 50% of 
responses were present for all PBC-40 domains (and 80% for all other secondary 
questionnaires) then the median value for the completed items in the domain was ascribed 
to any missing items. 
Baseline (BL) characteristics of the study population were summarized separately within 
each randomized group. The primary analysis was the PBC-40 fatigue domain: descriptive 
statistics were reported at each time point (baseline, 3, 6, 9 and 12 months) in both arms. 
PBC-40 fatigue domain scores were compared at 3 months between intervention and 
placebo group using multiple linear regression using a backward stepwise procedure (setting 
significance level at 10%) with adjustment forcing inclusion of baseline PBC-40 fatigue score, 
then selecting from age in years, UK PBC risk model score at 10 years prediction and patient 
location (managed by Newcastle center for at least one year or not) at baseline. The results 
were reported as an adjusted difference in means with a 95% confidence interval. The same 
approach was used when secondary outcomes were assessed. Bootstrap estimation was 
used throughout as it was not clear that the distributions were normal. The time course of 
the comparison between intervention and control groups over the 12 month follow-up 
period using time points above was assessed for PBC-40 fatigue domain using repeated 
measures Analysis of variance (ANOVA). The above analyses for PBC-40 fatigue score were 
repeated for secondary outcomes. Descriptive analyses were reported for biochemical and 
immunological measures. Additionally repeated measures ANOVA up to 12 months was 
carried out for bilirubin and serum alkaline phosphatase outcomes. The correlation between 
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degree of change in anaerobic threshold and change in fatigue over 3 months from baseline 
was also reported using Pearson’s correlation coefficient. The statistical software package 
StataIC (version 14o) was used for all analyses. 
 
Results: 
Subjects Disposition and Baseline Characteristics 
Recruitment to the trial took place between October 2012 and October 2015. Seventy-one 
participants were recruited into the trial. 57 were randomized, 7 were screen failures, 6 
patients withdrew and there was one death (unrelated to participation). Rates of attrition 
were low, with 50 participants staying in the trial for the full 12 months follow-up; 55 
provided outcome data at 3 and 6 months and 54 at 9 months with two participants being 
lost to follow-up and one withdrawn. (Figure 1). Patients’ baseline characteristics are 
presented in Table 1. Significant levels of both daytime somnolence (as assessed by the ESS) 
and vasomotor autonomic dysfunction (as assessed by the OGS) were seen at baseline in 
both the Rituximab and the placebo groups, with mean values exceeding the recognized 
values for clinical significance for both (10 for ESS and 4 for OGS; Supplementary Table 1).  
The mean age was 55 years old with the expected female predominance and all but one 
participant was white. In keeping with the study criteria, all participants exhibited significant 
fatigue.  
 
Primary Outcome 
Seventeen of the 27 (59%) Rituximab-treated patients and 10/28 (36%) of the placebo 
group achieved the pre-specific end-point of a drop of 5 or more units in the PBC-40. There 
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was no statistically significant difference in fatigue score at 3 months between Rituximab 
and placebo arms (adjusted mean difference -0.9 (95%CI - 4.6 to 3.1). However, 
improvement was observed in both arms (with mean score decreasing from 41.2 (Standard 
deviation SD=5.5) to 36.2 (SD=8.4) and 43.0 (SD=5.9) to 38.1 (SD=8.7) in the Rituximab and 
placebo arms, respectively (Figure 2, Supplementary Table 1). There was no significant 
difference between the two trial arms over the repeated assessments at 3, 6, 9 and 12 
months (Trial arms F=1.81, P=0.18; Arms x Time points F=0.41 P=0.80) (Supplementary 
Table 1). Fatigue diaries showed no statistically significant difference between the study 
groups (Supplementary Table 1), including in the assessments at 1 and 2 months 
suggesting there was no fatigue signal which we were missing by using a 3 month end-
point (data not shown). 
 
Secondary Outcomes  
Immunological analyses suggested that Rituximab was highly effective in mediating 
depletion of B-cells, its primary proposed mode of action (Figure 3a). No depletion was 
seen in the placebo arm. Complete depletion was maintained at 6 months with gradual 
repopulation to 50% of baseline by 12 months. Reduction in the levels of anti-PDC antibody 
was also seen in the Rituximab (but not placebo) group (Figure 3b) with peak reduction at 
6 months and sustained at 9 months. No correlation was observed, however, between 
reduction in anti-PDC antibody level with Rituximab treatment and reduction in fatigue 
(data not shown). Reduction in total immunoglobulin (Ig) and, in particular the IgM fraction 
was observed. Again reduction was incomplete in the Rituximab treated group and absent 
from placebo (Supplementary Table 2). 
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For the additional patient reported outcome measures (PROMs) - ESS, OGS, COGFAIL, 
HADS, PROMIS-HAQ and 5 non-fatigue domains of the PBC-40, the unadjusted and 
adjusted differences in mean scores between trial arms showed little difference at 3 
months, the 95% CIs were generally wide but there was no suggestion that the results 
were consistent with any clinically important differences (Supplementary Table 1). In 
contrast to fatigue, no notable improvement was seen in either group for the other 
measures. Any potential placebo effect was therefore restricted to fatigue. Physical activity 
levels (presented as Euclidian Norm minus One (ENMO) values) differed little between 
arms at 3 months: the adjusted mean ENMO levels were slightly lower in the Rituximab 
arm, but there was little indication of any meaningful difference (Supplementary Table 2). 
We used a combination of muscle MR spectroscopy and anaerobic threshold CPX to 
explore muscle bioenergetic function.  In keeping with previous reports, baseline anaerobic 
threshold was found to be low in the PBC patient group. Anaerobic threshold values at 3 
months rose significantly from baseline with Rituximab but not with placebo (adjusted 
difference 1.41, 95% CI 0.03 to 2.80; Figure 4a, Supplementary Table 3). There was, 
however, no apparent correlation between change in anaerobic threshold and change in 
fatigue over 3 months from baseline (Pearson’s correlation coefficient 0.12 (95% CI: -0.18 
to 0.40)). The minimum pH following the specific exercise task was highly variable amongst 
the PBC patients, with substantial acidosis seen in some patients. There was no statistically 
significant difference in minimum muscle pH following exercise between arms (Figure 4b, 
Supplementary Table 3). No significant reduction in the time taken to recover to baseline 
pH after exercise, and no reduction in the “area under the curve” for pH (a factor 
combining the degree of acidosis and the length of time taken to recover to baseline and 
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an estimate therefore of degree of muscle intracellular acid exposure) was seen in either 
arm. 
 
Exploratory Analysis  
RITPBC though not designed or powered to explore the impact of the drug on liver injury; 
did provide some insight into the impact of Rituximab therapy in early disease which could 
inform future trials of disease modifying therapy. Baseline biochemical parameters were 
typical of early-stage PBC. Median alkaline phosphatase values were 136 and 131 u/L in the 
Rituximab and placebo groups, respectively. There were no significant differences between 
trial arms or in the interaction between arms over time in repeated measure ANOVA up to 
12 months for bilirubin, but there were significant differences between trial arms (F=6.17, 
P=0.016) and in the interaction between arms over time (F=2.91, P=0.023) for ALP outcome 
(Supp Table 4 and 5). Median ALP fell from 136 to 106 u/L over 3 months in the Rituximab 
arm, whereas, the median ALP level rose from 131 to 137 u/L in the placebo arm. Ninety-
three percent of patients in the Rituximab arm had a normal ALP at 3 months compared to 
78% at baseline (65% from 61% in the placebo arm; Supp Table 6). All parameters 
progressively returned to baseline levels by 12 months of follow-up. 
 
Safety 
There were four serious adverse events (SAEs) during the course of the trial, none of which 
occurred in the active treatment group. One death from lobar pneumonia and Chronic 
Obstructive Pulmonary Disease (COPD) which occurred after consent, but prior to baseline 
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visit. One participant in the placebo arm was hospitalized for right optic neuritis and at a 
later date for left optic neuritis, but made a full recovery on both occasions. One 
participant in the placebo group was hospitalized for flare of chronic abdominal pain, but 
made a full recovery with opiate treatment.  
 
 
Discussion 
Fatigue is an important and complex clinical problem in PBC and is currently untreatable. 
Improvement in treatment is needed to enhance the life quality of patients. Improvement 
in fatigue with a mean reduction of over 5 units in the PBC-40 fatigue domain score (the 
predefined level for a clinically significant change) was observed in both the active drug 
and placebo groups. Gradual increase almost back to baseline levels was seen by 12 
months. The lack of beneficial effect on physical activity level, an objective measure that 
has relevance to the subjective domain of fatigue would further support the view that 
there is no significant fatigue improvement with Rituximab in PBC. On the basis of our 
findings there is, therefore, no evidence to support the use of Rituximab as a treatment for 
fatigue in otherwise unselected PBC patients, and there is no evidence to suggest that B-
cell related immune-phenomena play a significant role in fatigue pathogenesis in the 
disease. Levels of patient interest were, however, high amongst patients, as was retention 
within the study, both indicating a high degree of patient acceptability and supports the 
view that trials of therapy targeting symptoms in PBC are deliverable and highly acceptable 
to patients.
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B-cell depletion was complete in all the Rituximab treated patients, excluding a technical 
drug failure, with progressive re-constitution over the year of follow-up. Over a period of 
12 months, Rituximab was found to be safe. No SAEs were observed in the active drug 
group. In particular, no worsening of liver function was observed. This is in keeping with 
other reports of the agent in PBC and in contrast to the observation of worsening of liver 
function in murine models of PBC treated with anti-CD20 (19, 28, 29). This divergence of 
effects is likely to reflect the limitations of current murine models of PBC and challenges 
their relevance to therapeutics development. Rituximab had a benign safety profile in this 
trial. It is important to note, however, that follow-up was only for 12 months meaning that 
the possibility of late adverse sequelae cannot be excluded. 
Potential explanations for the apparent reduction of fatigue severity in the placebo arm 
include the placebo effect and regression to the mean. It is important to note also that the 
placebo arm patients received conditioning with Methylprednisolone as part of the study 
protocol and it is not possible to exclude an effect from this, although the time period 
between the last dose of conditioning (2 weeks) and the fatigue assessment primary end 
point (12 weeks) would argue against this.  Interestingly, the degree of response seen in 
the placebo group (36%) mirrors that seen in the placebo arm in recent trials of novel anti-
pruritic therapy in PBC suggesting that this may represent a natural placebo response rate 
in this symptomatic condition (30). This observation will help with the design of future 
studies of symptomatic therapy in the condition. It is striking that any change in levels of 
patient reported outcomes was restricted to the primary outcome parameter, fatigue. It is 
also interesting to observe that the restriction of a placebo effect to the primary outcome 
symptom seen in this trial is mirrored in recent trials of anti-pruritus therapy, where a 
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placebo effect was seen for pruritus severity but not fatigue. It is also notable that a 
placebo effect for fatigue was absent in the POISE trial of second-line Obeticholic Acid 
therapy in PBC where symptom impact of treatment was not a principal focus of the trial 
pathology and fatigue severity was substantially lower in the study population than in the 
current fatigue-focused trial (median PBC-40 fatigue domain 24 compared with 42). One 
approach to mitigating the placebo effect in future trials in PBC might be to make the 
target more generic (“symptom burden” rather than a specific symptom). The very specific 
nature of the placebo effect also raises the question as to whether psychological 
interventions may have a value in at least mitigating the impact of symptoms in individual 
patients.  
It is possible that our failure to recruit to the original planned group size may have 
introduced bias. Our experience was that exclusion criteria around possible chronic 
infection or malignancy resulted in a significant attrition rate in our cohort, reflecting 
largely age-related risk factors. In terms of study protocol it is possible that we missed an 
effect before the 3 month assessment, although the patient diary reporting in months 1 
and 2 would argue against this  
The variability in the apparent response to Rituximab was marked, raising the possibility 
that fatigue is heterogeneous in nature and that only a subgroup of patients, with a 
particular form of the disease, are responders to Rituximab. Since the design of the trial, it 
has become clear that a stratified approach to therapeutics in PBC may be highly effective; 
something which had previously been thought to be a major challenge using unselected 
patient approaches. The RITPBC trial used an unselected approach which may be a 
limitation. Again, subsequent to the design of the trial, it has become increasingly accepted 
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that central and peripheral fatigue have quite distinct characteristics in PBC. The 
underpinning data and study hypothesis in RITPBC were based on peripheral muscle 
abnormality (and peripheral fatigue). The study population showed, at baseline, 
appreciable levels of sleep disturbance and cognitive impairment which are features 
strongly associated with central rather than peripheral fatigue (31, 32). Given the proposed 
mechanism of action for Rituximab in the study it is possible that this is a disease group 
which may be unresponsive to the therapy.  We do not believe that there is, at present, 
any rationale for further trials of Rituximab in PBC. It is worthy of note that as further data 
emerge regarding Rituximab and its use in other inflammatory conditions such as Primary 
Sjogrens Syndrome so confidence regarding any beneficial effect on fatigue reduces (33, 
34) . 
Bioenergetic abnormality was seen at baseline in the participants, mirroring the findings in 
the original studies. In terms of the bioenergetic model for fatigue in PBC, a number of 
conclusions can be drawn. The first is that the previously described bioenergetic 
abnormality is confirmed in this study in a cohort of highly fatigued patients. The second is 
that anaerobic threshold impairment is reduced in patients along with depletion of anti-
PDC. Further analysis will be required to determine whether this link is causal, however the 
finding would be at least in keeping with the hypothesis that anti-PDC has a direct 
metabolic role increasing anaerobic metabolism. If this is indeed the case, it may be that 
the peak effect has been missed given that the peak in anti-PDC depletion was at 6 
months, 3 months after the last anaerobic threshold assessment. The third conclusion is 
that the link between anti-PDC and anaerobic threshold, and muscle bioenergetic 
abnormality and perceived fatigue is limited. Change in post-exercise muscle pH with 
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Rituximab was limited, as was any change in fatigue. The apparent disconnect between 
anaerobic threshold on one hand and muscle bioenergetics abnormality on MR 
spectroscopy on the other would suggest that factors other than the balance between 
aerobic and anaerobic metabolism play predominant role in regulating muscle pH. The 
obvious candidate would be the capacity of muscle to handle protons and lactate; capacity 
which may be modified by addressing autonomic dysfunction (highly prevalent in PBC and 
postulated to impact on both transport of protons and lactate out of muscle cells and 
vascular outflow from muscle tissue) or through exercise therapy (which is known to 
increase proton/lactate transporter levels and to increase vascular outflow (35). Both 
approaches have evidence, albeit very limited, to suggest efficacy in PBC (36).  
The trial was not designed or powered to explore the response of biochemical parameters 
to rituximab therapy, indeed a significant proportion of participants had normal serum 
biochemistry at baseline reflecting the lack of association between biochemical parameters 
of disease severity and fatigue severity. Interestingly, amongst the patients receiving 
rituximab therapy almost universal normalization of alkaline phosphatase was seen (with 
no comparable effect in the placebo group).  Trials of immunotherapy as second-line 
treatment in Ursodeoxycholic acid (UDCA) under-responsive patients, have to date been 
unsuccessful (37). One potential explanation for this lack of efficacy could be that, unlike in 
our study, the biological agents may have been used “downstream” in the disease 
pathway, following proven failure of treatment with UDCA when cholestatic injury is 
established.  
The conclusions of this study are firstly that trials of therapy for fatigue in PBC are highly 
acceptable, but the issue of a likely placebo effect will remain a real challenge that will 
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need to be addressed in future trial designs. The second is that the suppression in 
anaerobic threshold seen in PBC is apparently reversed by Rituximab therapy suggesting 
that there may be an antibody or other B-cell related process at play. The reduced post-
exercise pH in muscle in PBC and impaired recovery which has been linked to fatigue was 
not, in contrast, improved by Rituximab suggesting that this is not linked to the reduced AT 
and suggesting that alternative approaches to improving muscle pH, including exercise 
therapy, should be explored.  
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Figure Legends: 
Figure 1: Trial CONSORT diagram 
Figure 2: PBC-40 fatigue scores at baseline, 3 months (primary end-point) and 6, 9 and 12 
months. In the Rituximab and Placebo groups (primary endpoint) 
Figure 3: Immunological changes seen in the Rituximab and Placebo-treated groups. a) B-
cells as a proportion of the total CD45+ population. b) Serum anti-PDC level as a proportion 
of the baseline, pre-treatment value (secondary end-points).   
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Figure 4: Impact of Rituximab and Placebo on bioenergetics function in terms of a) 
Anaerobic Threshold and b) Minimum muscle pH following controlled exercise (secondary 
end-points). 
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 Table 1: 
 Rituximab 
(n=29) 
Placebo 
(n=28) 
 Median (IQR) Range Median (IQR) Range 
Age in years 55.9 (48.8-60.0) 34.0-66.7 53.3 (49.9-58.8) 39.2-72.1 
Alcohol consumption 
(units per week-
drinkers) 
4 (2-8) 1-12 4 (2-12) 1-14 
Alcohol consumption 
(units per week -ALL) 
1 (0-4) 0-12 0 (0-1.5) 0-14 
BMI 28.7 (24.5-30.5) 19.8-40.5 26.7 (22.9-30.7) 18.7-43.5 
  
n 
 
(%) 
 
n 
 
(%) 
Sex: Female 28 96.5 27 96.5 
Ethnicity:     
White 27 96.5 28 100 
Non-white 1 3.5 0 0 
Smoking status:     
Never 16 55 12 43 
Past 7 24 8 28.5 
Current 6 21 8 28.5 
Managed by 
Newcastle  
20 74 19 68 
UDCA use: Yes 24 89 27 96.5 
If yes: Responder 19 79 16 59 
Baseline Lab Parameters: 
 Mean (SD) Range Mean(SD) Range 
Hemoglobin (g/L) 127.8 (10.9) 104-152 131.0 (8.2) 110-151 
WBC (10
9
/L) 5.8 (1.5) 3.7-8.6 6.3 (1.4) 3.6-8.8 
Platelet count (10
9
/L) 274.6 (59.1) 132-397 276.9 (91.8) 105-444 
PT (secs)  10.9 (0.6) 10-12 11.0 (0.7) 10-13 
Bilirubin (mmol/L) 7.3 (3.9) 3-22 7.4 (3.7) 3-21 
Alkaline phosphatase 
(U/L) 
156.6 (72.4) 52-339 217.1 (166.8) 45-642 
ALT (U/L) 48.4 (33.0) 10-150 50.2 (29.2) 11-135 
AST (U/L) 45.0 (25.8) 19-128 46.6 (24.9) 14-105 
Albumin (G/L) 44.7 (2.1) 40-49 43.1 (2.2) 37-47 
GGT (U/L) 140.8 (157.7) 22-559 197.4 (224.5) 12-853 
APTT (secs) 34.0 (5.4) 26-52 32.8 (3.2) 28-43 
CRP  6.9 (5.5) 5-33 7.2 (4.8) 5-21 
Baseline Immunoglobulin levels: 
 Mean (SD) Range Mean(SD) Range 
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Total IgG: 12.5  (3.4) 
 
7.5-22.2 
 
11.8  (2.55) 
 
7.6-17.9 
 
Total IgM: 3.7 (2.1) 
 
0.9-8.7 
 
3.2 (2.1) 
 
0.5-10.3 
 
Total Ig level: 
 
18.6 (5.0) 
 
11.4-32 
 
17.1 (4.4) 
 
9.8-28.3 
 
Baseline UKPBC 40 Fatigue and 10 year UK PBC risk score: 
 
 
Mean (SD) Range Mean(SD) Range 
PBC-40  
Fatigue (11-55): 
41.2 (5.5) 
 
32-54 
 
43.0 (5.9) 
 
31-54 
 
 Median (IQR) Range Median (IQR) Range 
UK PBC risk score at 
10 years 
1.26 (0.94-1.74) 0.21-3.55 1.75 (1.12-3.04) 0.20-12.90 
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